John S. Zuzack - Concepedia

Author

John S. Zuzack

Cortech Solutions (United States)

Also Known As

J S Zuzack, J Zuzack, J. Zuzack, J.S. Zuzack, John S Zuzack, John S. Zuzack, John Zuzack

Publications

460

Citations

H-Index

Concepts

All Affiliations

Cortech Solutions (United States)University of Colorado Denver University of Delaware

About

John S. Zuzack is an author at Cortech Solutions (United States) specializing in medicine, drug discovery, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	329
2	Biochemistry	2	2	78
3	Biomolecular Engineering	2	2	95
4	Natural Sciences	1	1	30
5	Public Health	1	1	11

John S. Zuzack

Publications

425

Citations

H-Index

Page 1

	Year	Citations
A new generation of bradykinin antagonists John M. Stewart, Lajos Gera, W. L. Hanson, Immunopharmacology Molecular PharmacologyMedicineMechanism Of ActionNew GenerationPharmacotherapy	1996	93
Potent, long-acting bradykinin antagonists for a wide range of applications John M. Stewart, Lajos Gera, Daniel C. Chan, Canadian Journal of Physiology and Pharmacology ImmunologySelective B2 AntagonistNew GenerationSelective B1 AntagonistPharmacotherapy	1997	48
Potent, long-acting bradykinin antagonists for a wide range of applications John M. Stewart, Lajos Gera, Daniel C. Chan, Canadian Journal of Physiology and Pharmacology Molecular PharmacologyMedicineDrug DiscoveryMechanism Of ActionPharmacological Agent	1997	47
Bradykinin Receptor Antagonists Containing N-Substituted Amino Acids: <i>In Vitro</i> and <i>in Vivo</i> B<sub>2</sub> and B<sub>1</sub> Receptor Antagonist Activity Val S. Goodfellow, Manoj V. Marathe, Karen G. Kuhlman, Journal of Medicinal Chemistry	1996	30
Rationally designed non-peptides: Variously substituted piperazine libraries for the discovery of bradykinin antagonists and other G-protein-coupled receptor ligands Val S. Goodfellow, Christopher P. Laudeman, J. Ivan Gerrity, Molecular Diversity BiochemistryMedicineBradykinin AntagonistsNatural SciencesPeptide Engineering	1996	30
162 MEK162 (ARRY-162), a novel MEK 1/2 inhibitor, inhibits tumor growth regardless of KRas/Raf pathway mutations Shannon L. Winski, Daniel J. Anderson, Karyn Bouhana, European Journal of Cancer Supplements Tumor BiologyTumor Growth RegardlessNovel Mek 1/2Kras/raf Pathway MutationsMedicine	2010	30
Comparative profile of novel potent bradykinin antagonists at human B1 and B2 receptors Michael Burkard, John S. Zuzack, S. C. Jones, Immunopharmacology Molecular PharmacologyB2 ReceptorsComparative ProfileFunctional SelectivityMedicine	1996	28
New bradykinin antagonists having very high potency at B1 receptors Lajos Gera, John M. Stewart, Eric T. Whalley, Immunopharmacology Functional SelectivityMedicineImmunologyReceptor (Biochemistry)Neuropeptide Receptor	1996	25
Evidence of a bradykinin B1 receptor in human ileum: pharmacological comparison to the rabbit aorta B1 receptor. John S. Zuzack, Mike Burkard, David K. Cuadrado, Journal of Pharmacology and Experimental Therapeutics	1996	24
A new class of potent bradykinin antagonist dimers Lajos Gera, John M. Stewart, E. Whalley, Immunopharmacology MedicineRational Drug DesignNew ClassNon-peptide LigandPharmacology	1996	17

Page 1